Please try another search
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers episil oral liquid for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient’s bloodstream for the treatment of chemotherapy induced nausea and vomiting; and Darvias injection, and antineoplastic agent/organic arsenic product indicated for relapsed or refractory peripheral T-cell lymphoma. It is also involved in the development of SP-04, a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. The company was founded in 2006 and is based in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Stanley Lau | 67 | - | Independent Outside Director |
Susumu Araki | - | 2019 | Statutory Auditor |
Yoshiyuki Yamakawa | 59 | 2020 | Auditor |
Jiro Mizukawa | 69 | 2020 | Independent Outside Director |
Toshio Miyashita | 54 | 2014 | CFO, GM of Management Headquarters & Director |
Yoshihiro Arai | 61 | 2013 | President, CEO & Representative Director |
Norikazu Eiki | 74 | 2016 | Independent Outside Director |
Makoto Matsuo | 73 | - | External Corporate Auditor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review